Artoss, Inc. Announces Record Sales of NanoBone® Bone Graft
Press Release October 5, 2020
Artoss, Inc. is pleased to announce that it achieved record sales of NanoBone Bone Graft products in the third quarter of 2020.
Paul Byerley, Chief Executive Officer of Artoss, Inc., the exclusive North American distributors for NanoBone, said, “Through perseverance and diligent effort by our sales management and independent distributors, we accomplished record sales for the quarter. Our team’s continued hard work allowed us to achieve this milestone in the middle of a global pandemic. We are especially gratified to see new surgeon users and hospitals embrace the outstanding clinical outcomes and cost savings when using NanoBone as a standalone bone graft substitute.”
NanoBone Bone Graft harnesses the body’s inherent capacity to heal bone. FDA has cleared NanoBone for use as a standalone graft, including in spinal fusion, for its ability to create an osteogenic environment that replicates the architecture and chemistry found in natural bone. NanoBone products have been used in Europe and the US for more than fifteen years in more than 100,000 clinical cases across all indications. They have been available in the United States through Artoss, Inc. since 2015.
For further information, please contact:
425 E Saint Germain St., Suite 106
Saint Cloud, MN 56304